PD-1/PD-L1在非小细胞肺癌中的临床研究进展

Research progress on PD-1/PD-L1 in the treatment of non-small cell lung cancer

近年来,免疫治疗在癌症研究中取得了突飞猛进的发展。以程序性死亡受体-1(programmed cell death-1,PD-1)及其配体程序性死亡配体-1(programmed cell death-ligand 1,PD-L1)为靶点的免疫治疗药物在非小细胞肺癌(non-small cell lung cancer,NSCLC)的治疗中显示出了良好的疗效和耐受性,治疗前景值得期待。本文对PD-1/PD-L1治疗NSCLC的临床研究现状进行综述。

In recent years,immune therapy for the treatment of cancer has made remarkable progress.The monoclonal antibodies of programmed death-1（PD-1） and programmed death-ligand 1（PD-L1） have shown considerable responses and good tolerance in the treatment of non-small cell lung cancer（NSCLC）.In this review,we summarized the current clinical status and future direction of PD-1/PD-L1 in NSCLC.